Bone morphogenetic protein-4 compounded with platelet-rich plasma promotes bone healing

doi:10.3969/j.issn.2095-4344.2014.38.006

Abstract

Abstract:

BACKGROUND: Studies have shown that bone morphogenetic proteins play a key role in skeletal development. Platelet-rich plasma alone in animal or clinical trials cannot significantly promote bone graft healing.
OBJECTIVE: To investigate the osteogenesis effect of bone morphogenetic protein-4 compounded with platelet-rich plasma the bone defect area.
METHODS: Twenty-four New Zealand white rabbits were selected to establish maxillary bone defect models, and then were randomly divided into four groups, six rats in each group. Group A was blank control group; Group B was β-tricalcium phosphate (0.1 g)+Bio-gide group; group C was β-tricalcium phosphate (0.1 g)+Bio-gide+ platelet-rich plasma (1 mL) group; and group D wasβ-tricalcium phosphate (0.1 g)+Bio-gide+platelet-rich plasma (1 mL)+bone morphogenetic protein-4 (5 μg). Gross observation, histological observation and imaging analysis were performed for analysis of new bone formation at weeks 4, 8, 12 after modeling.
RESULTS AND CONCLUSION: After 4 weeks, group D had more new bone and vessels formed in the bone defect area than the group B (P < 0.01); however, the amount of new bone was higher in the group B than the group A (P < 0.01). After 4, 8, 12 weeks, the amount of new bone in the bone defect area was higher in the group D than the groups B and C (P < 0.01), and lowest in the group A (P < 0.01). In the β-tricalcium phosphate scaffold, platelet-rich plasma combined with bone morphogenetic protein can significantly promote the healing of bone defects.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: maxilla, bone morphogenetic proteins, platelet-rich plasma, calcium phosphates

CLC Number:

R318

Shi Jian-jie, Luo Zhi-bin, Chen Wen-xiong . Bone morphogenetic protein-4 compounded with platelet-rich plasma promotes bone healing[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(38): 6099-6104.

Figures/Tables 1

2.1 实验动物数量分析实验选用大白兔24只，分为4组，实验过程无脱失，全部进入结果分析。 2.2 兔骨缺损区大体观察大体标本可见12周时空白对照组成骨较差，缺损区中间凹陷，表面纤维组织增生；余各组成骨作用好，成骨饱满，表面光滑(图2)。 2.3 兔骨缺损区组织学观察 4周：富血小板血浆组、富血小板血浆+骨形态发生蛋白4组两组骨缺损处见新生血管丰富，其中富血小板血浆+骨形态发生蛋白4组可见较多的纤维性骨痂形成，局部见较多成骨细胞及软骨细胞增生活跃，骨移植颗粒开始降解，可见与骨干平行的骨样组织，富血小板血浆组见纤维组织生长，材料降解为网状，周围有炎性细胞和少量骨母细胞(见图3)。空白对照组、β-磷酸三钙+Bio-gide生物膜组两组骨缺损区见少量新生血管，β-磷酸三钙+Bio-gide生物膜组周可见大量散在骨粉颗粒及纤维组织结构，其间散在数量不等的成骨细胞和软骨细胞，成骨作用较对照组强。 8周：富血小板血浆+骨形态发生蛋白4组缺损区内骨粉颗粒明显较β-磷酸三钙+Bio-gide生物膜组、富血小板血浆组减少，伴随着大量骨样组织形成，钙化、沉积明显；β-磷酸三钙+Bio-gide生物膜组、富血小板血浆组局部见新生骨组织，少量破骨细胞，少量钙盐沉积，两组间差异无显著性意义；空白对照组出现以纤维性骨痂为主，自体骨边缘见少量新生骨组织，明显较β-磷酸三钙+Bio-gide生物膜组、富血小板血浆组少(图4)。 12周：富血小板血浆+骨形态发生蛋白4组主要为成熟骨，为板层骨，可见哈佛氏小管形成，散在少量编织骨，骨粉颗粒明显减少，少量破骨细胞(图5)。 2.4 组织学图像分析缺损区新生骨结果计算机图像分析显示，伴随愈合时间推移，新骨形成逐渐增多，β-磷酸三钙颗粒逐渐降解，其中富血小板血浆+骨形态发生蛋白4组12周时新生骨略高于8周但两者差异无显著性意义(P > 0.05)。术后4 周，富血小板血浆+骨形态发生蛋白4组新生骨略多于富血小板血浆组，但两组间差异无显著性意义 (P > 0.05) ，富血小板血浆组、富血小板血浆+骨形态发生蛋白4组两组骨缺损区新生骨以及新生血管均多于β-磷酸三钙+Bio-gide组实验侧(P < 0.01)，β-磷酸三钙+Bio-gide组新成骨多于空白对照组(P < 0.01)；术后4，8，12周，富血小板血浆+骨形态发生蛋白4组骨缺损区新生骨均多于β-磷酸三钙+Bio-gide组、富血小板血浆组两组骨缺损区(P < 0.01)，富血小板血浆组略多于β-磷酸三钙+Bio-gide组，但两者差异无显著性意义(P > 0.05)，β-磷酸三钙+ Bio-gide组、富血小板血浆组两组均多于空白对照组(P < 0.01)。"

References

[1] Carlsson L,Röstlund T,Albrektsson B,et al.Osseointegration of titanium implants. Acta Orthop Scand.1986;57(4):285-289.
[2] Joos U, Kleinheinz J. Reconstruction of the severely resorbed (Class VI) jaws: routine or exception?J Craniomaxillofac Surg.2000;28(1): 1-4.
[3] Balk SD.Calcium as a regulator of the proliferation of normal, but not of transformed, chicken fibroblasts in a plasma-containing medium. Proc Natl Acad Sci USA. 1971;68(2): 271-276.
[4] Hildner F, Albrecht C, Gabriel C, et al. State of the art and future perspectives of articular cartilage regeneration: a focus on adipose-derived stem cells and platelet-derived products. J Tissue Eng Regen Med. 2011;5(4):e36-51.
[5] Lee KS, Wilson JJ, Rabago DP, et al.Musculoskeletal applications of platelet-rich plasma: fad or future? AJR Am J Roentgenol.2011; 196:628–636
[6] Raghoebar GM, Schortinghuis J, Liem RS, et al.Does platelet-rich plasma promote remodeling of autologous bone grafts used for augmentation of the maxillary sinus floor?. Clin Oral Implants Res.2005;16(3): 349-356.
[7] Por YC, Barceló CR, Salyer KE, et al. Bone generation in the reconstruction of a critical size calvarial defect in an experimental model.J Craniofac Surg.2008;19(2): 383-392.
[8] Urist MR,Strates BS.Bone morphogenetic protein.J Dent Res.1971;50(6): 1392-1406.
[9] Reichert JC, Woodruff MA, Friis T, et al.Ovine bone- and marrowderived progenitor cells and their potential for scaffold-based bone tissue engineering applications in vitro and in vivo. J Tissue Eng Regen Med.2010;4:565-576.
[10] De Biase P, Capanna R. Clinical applications of MBP. Injury. 2005;36(Suppl 3):S43-S46.
[11] Deschaseaux F, Sensebe L, Heymann D . Mechanisms of bone repair and regeneration. Trends Mol Med.2009;15: 417-429.
[12] Wallace AL, Makki R, Weiss JB, et al. Measurement of serum angiogenic factor in devascularized experimental tibial fractures. J Orthop Trauma.1995;9(4): 324-332.
[13] Carreira AC1, Lojudice FH, Halcsik E, et al. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res.2014;93(4):335-380.
[14] Ali IH, Brazil DP. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br J Pharmacol.2014;171(15):3620-3652.
[15] Boerckel JD, Kolambkar YM, Dupont KM, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials.2011;32: 5241-5251.
[16] Karsenty G. The complexities of skeletal biology. Nature. 2003; 423: 316-318.
[17] Nakamura J, Yanagita M. Bmp modulators in kidney disease. Discov Med.2012; 13: 57-63.
[18] Wang EA, Rosen V, D'Alessandro JS,et al.Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A.1990;87(6): 2220-2224.
[19] Nakahara H, Takaoka K, Koezuka M, et al.Periosteal bone formation elicited by partially purified bone morphogenetic protein. Clin Orthop Relat Res.1989;(239): 299-305.
[20] Kim CS, Kim JI, Kim J, et al. Ectopic bone formation associated with recombinant human bone morphogenetic proteins-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers. Biomaterials.2005;26(15): 2501-2507.
[21] Degat MC, Ferreira E, Logeart-Avramoglou D. Use of growth factors in the repair of bone. Pathol Biol (Paris). 2005;53: 131-141.
[22] Ben-David D, Srouji S, Shapira-Schweitzer K, et al. Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials. 2013;34:2902-2910.
[23] Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res.1999; 367 (Suppl):95-106.
[24] Yang X, Han G, Pang X, et al. Chitosan/collagen scaffold containing bone morphogenetic protein-7 DNA supports dental pulp stem cell differentiation in vitro and in vivo. J Biomed Mater Res A. 2012; Feb 18. doi: 10.1002/jbm. a.34064. [Epub ahead of print]
[25] Polimeni G, Koo KT, Pringle GA, et al. Histopathological observations of a polylactic acid-based device intended for guided bone/tissue regeneration. Clin Implant Dent Relat Res.2008;10:99-105.
[26] Cestari TM, Granjeiro JM, de Assis GF,et al. Bone repair and augmentation using block of sintered bovine-derived anorganic bone graft in cranial bone defect model. Clin Oral Implants Res.2009;20:340-350.
[27] Salgado PC, Sathler PC, Castro HC, et al. Bone remodeling, biomaterials and technological applications: revisiting basic concepts.J Biomater Nanobiotechnol.2011;2:318-328.
[28] Hagi TT, Wu G, Liu Y, et al. Cell-mediated BMP-2 liberation promotes bone formation in a mechanically unstable implant environment. Bone.2010;46:1322-1327.
[29] Berner A, Boerckel JD, Saifzadeh S, et al. Biomimetic tubular nanofiber mesh and platelet rich plasma-mediated delivery of bmp-7 for large bone defect regeneration. Cell Tissue Res. 2012;347(3):603-615.
[30] 罗应伟,李松,沈丽宁. BMP-4 mRNA在Meckel’s软骨中的表达及意义.[J].昆明医学院学报,2004;25(3):9-12.
[31] Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury. 2005;36(12): 1392-1404.
[32] Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999;13(9):1055-1066.
[33] Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet- derived growth factor and its involvement in disease. Mayo Clin Proc.2006;81(9):1241-1257.
[34] Conover CA. In vitro studies of insulin-like growth factor I and bone. Growth Horm IGF Res. 2000; 10 Suppl B:S107-10. Review.
[35] Canalis E. Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest. 1980; 66(4):709-719.
[36] Tanaka H, Quarto R,Williams S,et al.In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone.1994; 15(6):647-53.
[37] Meraw SJ, Reeve CM, Lohse CM,et al.Treatment of peri-implant defects with combination growth factor cement. J Periodontol.2000;71(1):8-13.
[38] Sipe JB, Zhang J, Waits C, et al.Localization of bone morphogenetic proteins (MBP)-2,-4, and -6 within megakaryocytes and platelets. Bone.2004;35(6):1316-1322.
[39] Glowacki J. Angiogenesis in fracture repair. Clin Orthop Relat Res.1998;(355 Suppl): S82-89. 23.
[40] Salim A, Nacamuli RP, Morgan EF,et al.Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem.2004;279(38): 40007-40016.